scholarly journals 40. A case of large vessel vasculitis presenting with limb claudication symptoms

2019 ◽  
Vol 3 (Supplement_1) ◽  
Author(s):  
Ursula Laverty ◽  
Michelle McHenry

Abstract Introduction This is a case report of extensive large vessel vasculitis which initially presented to the vascular team with limb claudication symptoms and an absent radial pulse. CT angiogram was suggestive of a large and medial vessel arteritis, without a significant elevation in ESR. Case description A 71-year-old gentleman was referred from the vascular team to the rheumatology outpatient clinic. He initially attended orthopaedics and was awaiting shoulder surgery. He reported pain and intermittent colour changes in his left hand and was noted to have an absent radial pulse. CT angiogram was suggestive of a large and medium vessel arteritis such as giant cell arteritis. The CT aorta showed occlusion of the left axillary artery with significant narrowing of the left subclavian. He had a known history of cataracts, mixed frequency hearing loss, cervical spondylosis and previous arthroscopic sub acromial decompression surgery. He had intermittent mild jaw pain for a few months but no other clinical symptoms in keeping with vasculitis. He had no headache, scalp tenderness or constitutional symptoms. ESR was 41. Temporal artery biopsy was positive. Histology was in keeping with temporal arteritis but there was no giant cells or granulomata seen. CT PET showed increased tracer uptake within the subclavian, axillary and the common carotid arteries bilaterally. There was also slightly increased tracer extending inferiorly to the aortic arch and within the proximal descending thoracic aorta. He was commenced on 60mg prednisolone OD, omeprazole, adcal D3, alendronate, aspirin and cotrimoxazole. A month later, he presented with chest pain and was diagnosed with acute coronary syndrome. He had extensive imaging and there was no evidence of dissection. He had five coronary stents inserted and was commenced on dual anti platelet therapy for one year. He was commenced on tocilizumab as a steroid sparing agent taking into consideration the severity and extent of his disease, the need for dual antiplatelet therapy and increased bleeding risk. Discussion This was an interesting case of extensive large vessel vasculitis without a significant inflammatory response. He had extensive disease with both large vessel and cranial involvement. We held off on steroid treatment until he was investigated with CT PET and biopsy as his symptoms were longstanding. He was a high risk candidate for long term steroids given his recent MI and need for dual antiplatelet therapy. We opted for tocilizumab as a steroid sparing agent given the extent and severity of vessel involvement and increased bleeding risk on antiplatelet treatment. Tocilizumab is licensed for relapsing and remitting GCA and has the ability to limit steroid use and reduce the risk of relapse. Tocilizumab was used as an effective steroid sparing agent in this case. Key learning points This case has shown that extensive large vessel involvement can be seen in vasculitis without a significantly inflammatory response. ESR was only 41 in this case despite the extent of vasculitis. Therefore we must keep an open mind when considering a diagnosis of vasculitis as inflammatory markers may be normal. Tocilizumab was used an effective steroid sparing agent and has helped to limit steroid use in the setting of increased bleeding risk. In patients presenting with these clinical findings, we would have a low threshold for requesting temporal artery biopsy. This patient has established damage due to the extensive vessel involvement and it will be difficult to assess whether symptoms are related to damage or disease activity. How do we best assess whether symptoms are related to damage or disease activity? What is the best imaging to monitor disease activity? How best do we manage this patient’s disease in the long term due to the extent of vessel involvement? Conflicts of interest The authors have declared no conflicts of interest.

Rheumatology ◽  
2021 ◽  
Vol 60 (Supplement_1) ◽  
Author(s):  
Owen Cronin ◽  
Neil D McKay ◽  
Hannah Preston ◽  
Helen Harris ◽  
Barbara Hauser

Abstract Background/Aims  Giant cell arteritis with large vessel vasculitis (LV-GCA) represents a distinct, less researched sub-category of giant cell arteritis (GCA). In comparison to cranial GCA, the patient’s diagnostic pathway is less well described and it is thought that LV-GCA is underdiagnosed, including in patients with polymyalgia rheumatica and cranial-GCA. Advances in imaging (e.g. PET-CT) and treatment (tocilizumab), have provided additional options in the diagnosis and management of LV-GCA. The aim was to describe the contemporary clinical journey for patients diagnosed with LV-GCA. Methods  The electronic patient health record system in NHS Lothian (TrakCare) was used to collect relevant data. Patients with imaging-confirmed large vessel vasculitis, diagnosed with GCA after 1 January 2017 were included. Follow-up was until August 2020. Results  Eighteen patients with LV-GCA were included. The mean age was 65 years and 66.7% were female. Two patients had known cranial-GCA but 89% of patients were diagnosed exclusively with large vessel involvement. The most common symptoms were malaise (55%), weight loss (55%), polymyalgia rheumatica (55%) and limb claudication (44%). Pyrexia of unknown origin was a feature in only 17% of patients. Two patients were asymptomatic and were investigated on the basis of raised inflammatory markers. Mean CRP at baseline was 99mg/L and ESR 85mm/hour. The mean time from symptom-onset to diagnosis was 6.8 months (range 1 to 15 months). Sixteen patients (89%) were reviewed by at least one other secondary care specialist. One third of patients were referred from General Medicine followed by Vascular Surgery (16%) and General Practice (16%). 7/18 patients were inpatients at the time of referral. 56% of patients required two modalities of imaging to confirm large vessel involvement. The most commonly used imaging techniques (in descending order) were CT-Chest/Abdomen/Pelvis, CT-angiogram, PET-CT and Vascular Ultrasound. 50% of patients underwent follow-up imaging, most commonly MR- or CT-angiography. Mean follow-up was for 1.6 years. The mean prednisolone dose at 3 months (n = 18) was 24mg daily and 8mg at 12 months (n = 12). 28% of patients relapsed during the follow-up period at 4, 5, 8, 9 and 24 months post-diagnosis. 7/18 patients were commenced on methotrexate for steroid-side effects or for relapse. 8/18 received subcutaneous tocilizumab in combination with methotrexate in two cases. Three patients were started on azathioprine but only one continued. Conclusion  In modern-day clinical practice, patients with LV-GCA experience a longer time to diagnosis than those with cranial symptoms. Patients with LV-GCA can experience an array of constitutional symptoms. Frequently, more than one imaging modality is required to confirm LV-GCA and the majority of patients will have seen other hospital specialists or have been admitted to hospital before diagnosis. Methotrexate and tocilizumab are the most frequently-used and effective steroid-adjunct in this single-centre cohort. Disclosure  O. Cronin: None. N.D. McKay: Consultancies; Gilead. Other; Has received support for conference attendance from Pfizer and Gilead, Has received educational support from UCB, Gilead, Celgene, Biogen, Sanofi, Abbvie, Novartis, Pfizer. H. Preston: None. H. Harris: None. B. Hauser: None.


2019 ◽  
Vol 3 (Supplement_1) ◽  
Author(s):  
Hira Ghuman ◽  
Muditha Samaranayaka

Abstract Introduction Large vessel vasculitis (LVV) is a heterogeneous group of conditions, comprising of giant cell arteritis (GCA) and Takayasu arteritis (TAK). The American College of Rheumatologists (ACR) criteria provides a scoring system based on age, symptoms, and clinical examination findings, investigations to reach a diagnosis of either GCA or TAK. Similarly, European League Against Rheumatism (EULAR) recommendations discuss various imaging modalities in visualising vascular inflammation. Management is typically glucocorticoids, but for relapsing disease the challenge is finding suitable glucocorticoid-sparing agents. Here we describe a case of LVV presenting with great diagnostic complexity, discussing diagnostic modalities, treatment options and complications of therapy. Case description A 64-year-old female was referred to rheumatology clinic following extensive negative investigations, apart from on-going inflammatory response under gastroenterology for unexplained weight loss for over a year. Further history revealed lower limb cramps, fatigue and frontal headaches. She did not report any jaw claudication or visual disturbances but had atypical neck pain. As the main carer for her mother with dementia all these symptoms led to significant functional impairment and a great deal of anxiety for the patient. Under the gastroenterologists, she has had negative upper and lower GI endoscopies, CT thorax, abdomen and pelvis, labelled white cell scan and isotope bone scan in addition to a comprehensive septic screen including spinal imaging. A diagnosis of systemic vasculitis was suspected. ANCA screen was negative. Patient declined a superficial temporal artery biopsy. A FDG PET scan confirmed increased activity in medium and large sized vessels, such as the common carotids, descending thoracic aorta, vertebral arteries, and femoral arteries. Sites of metabolic hypersignal were consistent with large vessel vasculitis. Previous CT angiography was reviewed once again. No evidence of TAK was identified. GCA-LVV was decided as the most likely diagnosis.  The patient responded well to induction oral steroids with marked and rapid improvement in the inflammatory response. During the weaning down of steroids, the weight loss and the inflammatory response recurred.  Steroid sparing therapy was added on. Azathioprine was shortly discontinued owing to deranged liver function tests despite normal TPMT levels. Methotrexate was stopped as it caused suspected acute pneumonitis.  Oral bisphosphonates were not tolerated and she was listed for IV. Shortly after, she suffered a low trauma fracture neck of femur which caused fat emboli leading to a dense stroke. She recovered gradually with anticoagulation. Currently she is being screened for SC tocilizumab.   Discussion Diagnosing LVV can be challenging owing to non-specific symptoms at presentation. Although our patient’s presentation of fatigue, weight loss and worsening inflammatory markers were reflective of a vasculitis-like pathology from the onset, confirming the exact diagnosis was far from straightforward. LVV has countless clinical manifestations with new onset headaches being the most predominant. Limb claudication, another presenting symptom, is described in literature as a clinical manifestation of LVV in 5-15% of cases. The patient’s complaint of neck pain is also a feature associated with external carotid artery disease.  Various imaging modalities, including MRI, CT angiogram, and FDG PET scans have been implicated in the diagnosis of LVV. Currently, no diagnostic threshold exists beyond which uptake is defining of vasculitis. One study (n = 40) evaluating diagnostic accuracy of PET scans in LVV cases against control patients, calculated 80% specificity and 65% sensitivity. Whereas, another study (n = 24) reported 100% specificity in use of PET scans for diagnosis of extracranial GCA.  A second dilemma encountered in this case following LVV diagnosis, was concluding the subtype. The patient’s diminishing pulses, a characteristic feature of TAK, was evaluated using angiography techniques. Results were inconsistent with the expected characteristic aortic stenosis or occlusions described by TAK diagnostic criteria. Despite no histological assessment from superficial temporal arteries, due to lack of scalp tenderness and jaw claudication, diagnosis was confirmed and managed as GCA-LVV.   This case was further complicated by finding a management regime both effective at tackling GCA-LVV activity, but also suitable for the patient. Disease which follows a relapsing course is indication for glucocorticoid-sparing agents. Published data is increasingly favouring use of tocilizumab, with a randomised control trial (n = 251) showing sustained remission in around 56% of patients. The aim with our patient remains finding a balance between adverse side effects and medication efficacy.  Key learning points LVV is frequently the least obvious diagnosis, but nonetheless an important differential in a rheumatology clinic. The journey to diagnosing LVV is convoluted, either taking the route of temporal artery biopsy or various radiological imaging to gain an answer. This case highlights the broad extent of clinical manifestations of LVV, such as limb claudication.  In atypical presentations, with limited feasibility for histological studies, radiological imaging of arterial morphology has proven pivotal in reaching a diagnosis of LVV. A key finding for GCA on ultrasound is the ‘halo’ sign’. The role of MRI has been evaluated in identifying changes in arterial wall thickness and enhancement of only temporal and occipital arteries. CT angiogram can demonstrate signs of active vessel disease more centrally. PET scans, although utilise ionising radiation, image the aorta and its branches in detail- therefore, guiding diagnosis.  This case would benefit the audience by demonstrating the diagnostic and treatment dilemmas in LVV. It will also highlight the disease burden of vasculitis especially due to the rare adverse effects this patient suffered due medication. The conference would be a platform for the authors to learn from the experiences of various clinicians, around the diagnosis of LVV and to share with the department. We would very much like to have feedback from the experts in the field and also learn more about advances in biomarkers, like interleukins, now linked to LVV. Conflicts of interest The authors have declared no conflicts of interest.


Rheumatology ◽  
2018 ◽  
Vol 58 (4) ◽  
pp. 609-616 ◽  
Author(s):  
Pierluigi Macchioni ◽  
Luigi Boiardi ◽  
Francesco Muratore ◽  
Giovanna Restuccia ◽  
Alberto Cavazza ◽  
...  

Abstract Objective To evaluate the influence of disease-related findings and treatment outcomes on survival in a population-based cohort of Northern Italian patients with GCA. Methods A total of 281 patients with incident temporal artery biopsy (TAB)-proven GCA, diagnosed over a 26-year period (1986–2012) and living in the Reggio Emilia area, were retrospectively evaluated. We analysed clinical, imaging and laboratory findings at diagnosis, pathological patterns of TAB, CS treatment and therapeutic outcomes, and traditional cardiovascular risk factors as factors predictive of survival. Results Univariate analysis showed that increased mortality was associated with large vessel involvement at diagnosis [hazard ratio (HR) 5.84], while reduced mortality was associated with female sex (HR 0.66), PMR (HR 0.54), higher haemoglobin levels (HR 0.84) at diagnosis, long-term remission (HR 0.47) and inflammation limited to adventitia or to the adventitial vasa vasorum (HR 0.48) at TAB examination. Multivariate analysis confirmed the association between increased mortality and large vessel involvement (HR 5.14) at diagnosis, between reduced mortality and PMR (HR 0.57) at diagnosis and adventitial inflammation (HR 0.31) at TAB. Conclusion PMR at diagnosis and inflammation limited to the adventitia at TAB appear to identify subsets of patients with more benign disease, while large vessel involvement at diagnosis is associated with reduced survival.


2019 ◽  
Vol 3 (Supplement_1) ◽  
Author(s):  
Shawki El-Ghazali ◽  
Maxine Hogarth

Abstract Introduction Large-vessel vasculitis in older patients is typically associated with giant cell arteritis (GCA) usually presenting with cranial features. GCA can also present with a primarily extra-cranial pattern as large-vessel GCA (LV-GCA). Takayasu arteritis is a large-vessel vasculitis that affects younger females and classically involves the aorta and its major branches. This condition can clinically manifest with claudication of the extremities, impaired peripheral pulsation and systemic symptoms. Features of Takayasu arteritis and LV-GCA can overlap.  This case reviews that of a 65-year-old lady with features of non-cranial large-vessel vasculitis and the approach taken to manage her case. Case description A 65-year-old female developed pains affecting the shoulder and forearms over a period of weeks. She additionally noted pins and needles of the affected limbs. Symptoms were worse with use and consistent with claudication. She denied systemic symptoms, headache, visual changes or early morning stiffness. She was referred to the emergency department for assessment. Blood pressure could not be obtained and radial pulses were absent. She was subsequently arranged for further investigation via the vascular team. CT angiogram of the upper limbs demonstrated diffuse significant subclavian and axillary artery stenoses bilaterally with appearances deemed suggestive of underlying vasculitis. She was referred for rheumatological assessment. CRP was 50 and MRA aorta confirmed findings identified on CT scan. Prednisolone was initiated at a dose of 60mg daily for 4 weeks, and was subsequently decreased at an initial rate of 10mg every 2 weeks. Methotrexate was started at a dose of 15mg weekly. Inflammatory markers were noted to improve and CRP decreased to normal range. Despite this, although her paraesthesia resolved, she reported only a modest improvement of her upper limb claudication symptoms. Blood tests were monitored, however shortly after starting methotrexate, ALT significantly increased to 1002 IU/L. Autoimmune and viral hepatitis screen returned negative, US abdomen was suggestive of fatty liver changes but was otherwise unremarkable. Rise in ALT was attributed to methotrexate use and this was stopped, and levels improved. Mycophenolate was thus introduced as an alternative at a dose of 1g BD, but unfortunately resulted in recurrence of raised ALT. At present, she is being managed with prednisolone alone, of which is slowly being reduced. Her case is being additionally reviewed at our local vasculitis centre based at Hammersmith Hospital for consideration of tocilizumab should there be difficulties on steroid reduction. Discussion Takayasu arteritis is a rare systemic large vessel vasculitis. Incidence is 1-2 per million annually with a female preponderance of 80-90%. Based on ACR classification criteria, the above patient would meet the diagnosis of this condition. Takayasu arteritis would normally be expected for those aged <40 years and has a median onset of 25-30 years. Due to her age, the diagnosis of large vessel vasculitis would be therefore be more consistent with LV- GCA, primarily in the absence of cranial features. Aorta and branch involvement can occur in up to 15% of GCA cases. Histologically, both GCA and Takayasu arteritis share similar findings and cannot be relied upon for diagnostic differentiation. Due to overlap of features, formal diagnostic labelling can be difficult in cases such as the one described. In regards to the management of her case, the general principle was taken of initial high dose prednisolone which has been gradually reduced. Introduction of DMARD therapy was implemented early which would be more typical for Takayasu arteritis rather than GCA. Unfortunately due to deranged ALT attributed initially to methotrexate, and subsequently mycophenolate, she is not currently on any steroid sparing treatment. Studies have demonstrated efficacy of IL-6 inhibition in managing large vessel vasculitis and as mentioned, her case is being reviewed with our local vasculitis centre for consideration of tocilizumab should there be difficulties on prednisolone weaning. Although CRP is now within normal range with treatment, our patient has ongoing claudication symptoms of the upper limbs. It is felt that this is likely due to residual vascular stenotic changes rather than current active vasculitis. As such, following stabilisation of her condition, consideration would be made for vascular surgical intervention in future. Key learning points Diagnosis of Takayasu versus giant cell arteritis can present a diagnostic challenge in some older patients due to overlap of typical features. The underlying process of large vessel vasculitis and shared components in both these conditions suggest they are within the same spectrum of disease. We discussed our management approach of high dose prednisolone which would be typically utilised in either diagnosis. In our case, due to drug induced hepatitis from methotrexate and subsequent mycophenolate, current management is with prednisolone alone. In regards to long term steroid sparing therapy, other options including IL-6 inhibition is being considered pending response to current treatment. Vascular surgical intervention for residual stenoses will also be reviewed following stabilisation of underlying inflammation. Conflicts of interest The authors have declared no conflicts of interest.


2019 ◽  
Vol 3 (Supplement_1) ◽  
Author(s):  
Faidra Laskou ◽  
Philip Sajik ◽  
Leena Yalakki

Abstract Introduction Takayasu arteritis (TA) is a large-vessel vasculitis that preferentially affects the aorta and its major branches, is rare, predominately affects women of child-bearing age and its precise aetiology is unknown. TA causes chronic vascular inflammation. Sarcoidosis, too, is a systemic inflammatory condition which can affect any organ system; the pulmonary system is the most common site. Large-vessel vasculitis is rare in sarcoidosis, but overlap between the two conditions has been reported. It is unclear whether they co-exist or manifest as one disease entity. We report a case of a 50-year-old lady with pulmonary sarcoidosis on a background of TA. Case description A 40-year-old female presented in 2010 with constitutional symptoms, erythema nodosum (confirmed on biopsy), audible murmurs over her carotids and subclavian arteries and raised inflammatory markers (CRP 100). She was diagnosed with Takayasu arteritis following CT angiogram which demonstrated periarterial cuffing and thickening of her carotids, subclavian and thoracic aorta. Her medical history consist of pericarditis in 1992, a thromboembolic event in 1995, ulcerative keratitis in 2006 and incidental aortic regurgitation in 2009.  She was treated with oral corticosteroids and started on azathioprine as a steroid sparing agent. Inflammatory markers normalised. Further cardiology assessments confirmed evidence of a dilated ascending aorta in 2015 and she was also diagnosed with corneal ulceration in September 2016. In July 2017, intermittent ankle swelling was reported which was associated with mildly raised inflammatory markers (CRP of 12, ESR of 27). Accentuating murmurs noted and in view of raised inflammatory markers, CT angiogram was repeated; that showed stable appearances of TA.  In May 2018, her azathioprine was reduced to 100mg from 125mg as she remained clinically and radiologically stable. In July 2018, she reported recurrence of night sweats and she had marginally raised CRP of 7 and ESR of 8. PET-CT, to look for active TA, demonstrated high uptake on bilateral mediastinal lymph nodes and no evidence of active TA. It was noted retrospectively that mediastinal lymphadenopathy was present on her CT back in 2017. She then underwent endobronchial ultrasound bronchoscopy in August 2018 which showed reactive lymph nodes. Other potential causes were excluded by extensive microbiological and immunology studies. Mediastinoscopy and lymph node excision was arranged as a lymphoproliferative/infective disease needed to be excluded in view of prolonged immunosuppression. Biopsy supported the diagnosis of sarcoidosis showing granulomatous changes. Oral prednisolone 40mg initiated and azathioprine was increased to 125mg. ACE levels remained normal. Discussion This case report emphasises the need for consideration of other systemic conditions in patients with known inflammatory diseases as they can co-exist. Patients who are presented with symptoms that are not fully consistent with a specific phenotype of a disease as in this case the ocular symptoms (corneal ulceration, ulcerative keratitis) and the erythema nodosum, could raise the possibility of a different or co-existent disease. It does also suggest that the prevalence of TA, or related forms of arteritis, may be higher than expected and should be considered, especially in younger patients with non-characteristic cardiovascular symptoms and suspected systemic inflammatory disease.  Moreover, the association with sarcoidosis in this and other previously described cases suggests that the two diseases may be related, and that TA or TA-like vasculitis may even be a complication of sarcoidosis. Other causes of large vessel vasculitis should be excluded as TB and lymphoproliferative diseases which can also present with lymphadenopathy especially as it is well known that large vessel vasculitis, especially in elderly population, could be part of a para-neoplastic syndrome.  Other diseases have been reported associated with TA but rarely sarcoidosis. TA and sarcoidosis may be related as they are characterized by certain nonspecific immunoinflammatory abnormalities. In most case reports sarcoidosis precedes TA diagnosis. In this case, TA was found 9 years before the diagnosis of sarcoidosis was made. Key learning points TA can precede the diagnosis of sarcoidosis. In case of relapsing or refractory TA, further investigations should be considered to exclude other co-existent pathologies as sarcoidosis. TA and sarcoidosis may be related as they are characterized by certain nonspecific immunoinflammatory abnormalities. It has been reported that TA stands as pathology-associated with sarcoidosis. Complete vascular clinical examination should be performed to detect inflammatory arteritis, especially in cured sarcoidosis presenting a relapse of the biological inflammatory process. Conflicts of interest The authors have declared no conflicts of interest.


2021 ◽  
Vol 80 (Suppl 1) ◽  
pp. 658.1-658
Author(s):  
F. Regola ◽  
F. Franceschini ◽  
G. Bosio ◽  
P. Toniati

Background:GCA is the most frequent systemic vasculitis in patients older than 50 years involving medium-sized and large arteries. On July 2019 EULAR published its updated recommendations for the management of large vessel vasculitis, including GCA.Objectives:To analyze how the application of the updated EULAR recommendations changed clinical practice in GCA patients in our Hospital.Methods:All patients with a new diagnosis of GCA between January 1st, 2018 and December 31st, 2020 were enrolled in this study. Two cohorts were analyzed: patients who received GCA diagnosis in the eighteen months before EULAR recommendations publication (between January 1st, 2018 and June 30th, 2019: cohort A) and patients who received GCA diagnosis in the following eighteen months (between July 1st, 2019 and December 31st, 2020: cohort B). Data are expressed as median (IQR).Results:70 patients were enrolled in the study (F: 47, M: 23, age: 76 (69-79) years): 39 patients in cohort A, 31 in cohort B. Table 1 summarize main clinical features and treatment of patients. Sixteen patients of cohort A (41%) and eleven patients of cohort B (35%) presented large vessel involvement demonstrated by FDG-PET/CT. Thirty-one patients in cohort A (79%) and twenty-seven in cohort B (87%) presented cranial symptoms and were studied with temporal arteries ultrasound (US) and/or biopsy (TAB). More specifically, in cohort A US was performed in 42% of patients with cranial symptoms and TAB in 58% of them. After EULAR recommendations publication (cohort B) the percentage of patients with cranial symptoms who performed US increased to 56% and the percentage of TAB decreased to 52%.After EULAR recommendations publication, time between symptoms onset and first rheumatologic evaluation was reduced by 30% (from 61 (23-131) to 43 (22-92) days).No difference in treatment regiments were found between groups, whether in glucocorticoid initial dose or DMARDs adjunctive therapy.Conclusion:After EULAR recommendations publication, two major improvement were achieved in our cohort. EULAR suggests GCA patients should be urgently referred to a specialist team. Consistently with this recommendation, time between symptoms onset and first rheumatologic evaluation was markedly reduced. Moreover, EULAR suggests always confirming GCA diagnosis by imaging or TAB, with US as first choice. In line with these recommendations, in our cohort US became more and more frequently performed and progressively preferred over TAB. On the other hand, no differences in treatment regiments were found over time, with EULAR recommendations satisfied both before and after their publication.References:[1]Hellmich B, et al. Ann Rheum Dis 2019.ALL GCA(n: 70)Before EULAR recommendations(n: 39)After EULAR recommendations (n: 31)Time between symptoms onset and first rheumatologic evaluation (days)53 (22-110)61 (23-131)43 (22-92)Temporal artery US28/58 (48%)13/31 (42%)15/27 (56%)Temporal artery biopsy32/58 (55%)18/31 (58%)14/27 (52%)Large vessel involvement (FDG-PET/CT)27 (39%)16 (41%)11 (35%)Glucocorticoid initial dose (mg/die prednisone equivalent)50 (47-50)50 (50-50)50 (38-50)DMARDs43 (61%)24 (61%)19 (61%)Disclosure of Interests:None declared


2021 ◽  
Vol 13 ◽  
pp. 1759720X2110090
Author(s):  
Donatienne de Mornac ◽  
Olivier Espitia ◽  
Antoine Néel ◽  
Jérôme Connault ◽  
Agathe Masseau ◽  
...  

Background: Giant cell arteritis (GCA) is the most common systemic vasculitis. Relapses are frequent. The aim of this study was to identify relapse risk factors in patients with GCA with complete large-vessel imaging at diagnosis. Methods: Patients with GCA followed in our institution between April 1998 and April 2018 were included retrospectively. We included only patients who had undergone large vascular imaging investigations at diagnosis by computed tomography (CT)-scan and/or positron emission tomography (PET)-scan and/or angio-magnetic resonance imaging (MRI). Clinical, biological, and radiological data were collected. Relapse was defined as the reappearance of GCA symptoms, with concomitant increase in inflammatory markers, requiring treatment adjustment. Relapsing patients (R) and non-relapsing patients (NR) were compared. Relapse and multiple relapses (>2) risk factors were identified in multivariable Cox analyses. Results: This study included 254 patients (73.2% women), with a median age of 72 years at diagnosis and a median follow up of 32.5 months. At diagnosis, 160 patients (63%) had an inflammatory large-vessel involvement on imaging, 46.1% (117 patients) relapsed at least once, and 21.3% (54 patients) had multiple relapses. The median delay of first relapse after diagnosis was 9 months. The second relapse delay was 21.5 months. NR patients had more stroke at diagnosis than R ( p = 0.03) and the brachiocephalic trunk was involved more frequently on CT-scan ( p = 0.046), as carotids ( p = 0.02) in R patients. Multivariate Cox model identified male gender [hazard ratio (HR): 0.51, confidence interval (CI) (0.27–0.96), p = 0.04] as a relapse protective factor, and peripheral musculoskeletal manifestations [HR: 1.74 (1.03–2.94), p = 0.004] as a relapse risk factor. Peripheral musculoskeletal manifestations [HR: 2.78 (1.23–6.28), p = 0.014], negative temporal artery biopsy [HR: 2.29 (1.18–4.45), p = 0.015], large-vessel involvement like upper limb ischemia [HR: 8.84 (2.48–31.56), p = 0.001] and inflammation of arm arteries on CT-scan [HR: 2.39 (1.02–5.58), p = 0.04] at diagnosis were risk factors of multiple relapses. Conclusion: Male gender was a protective factor for GCA relapse and peripheral musculoskeletal manifestations appeared as a relapsing risk factor. Moreover, this study identified a particular clinical phenotype of multi-relapsing patients with GCA, characterized by peripheral musculoskeletal manifestations, negative temporal artery biopsy, and large-vessel involvement with upper limb ischemia or inflammation of arm arteries. Plain language Summary At giant cell arteritis diagnosis, large-vessel inflammatory involvement is predictive of multiple relapses 46.1% of patients with GCA relapse, and 21.3% undergo multiple relapses; Male gender appears as a protective factor for relapsing in GCA; Peripheral musculoskeletal manifestations are a relapse and multiple relapses risk factor; A negative temporal artery biopsy is predictive of multiple relapses; Large-vessel involvement is predictive of multiple relapses.


2020 ◽  
Vol 108 ◽  
pp. 102419 ◽  
Author(s):  
Mathieu Vautier ◽  
Axelle Dupont ◽  
Hubert de Boysson ◽  
Chloé Comarmond ◽  
Tristan Mirault ◽  
...  

2018 ◽  
Vol 24 (1) ◽  
pp. 79-88 ◽  
Author(s):  
Amer Harky ◽  
Matthew Fok ◽  
Damian Balmforth ◽  
Mohamad Bashir

Despite being recognised over a century ago, the aetiology and pathogenesis of large vessel vasculitis (LVV) still remains elusive. Takayasu’s arteritis (TA) and giant cell arteritis (GCA) represent the two major categories of LVV, each with distinctive clinical features. Over the last 10 years an increased understanding of the immunopathogenesis of the inflammatory cascade within the aortic wall has revived the view that LVVs may represent subtypes of the same pathological process, with implications in the treatment of this disease. In this review, the histological, genetic and immunopathological features of TA and GCA will be discussed and the evidence for a common underlying disease mechanism examined. Novel markers of disease activity and therapies based on advances in our understanding of the immunopathogenesis of these conditions will also be discussed.


Sign in / Sign up

Export Citation Format

Share Document